Table 2.

Effect of Acthar treatment, initiated following onset of relapse, on EAE clinical disease in comparison to Placebo and no treatment in SJL/J female mice.

Treatment	n	Clinical score day before treatment (day 30)	Clinical score on treatment day 1 (day 31)	Peak clinical score on relapsea	Cumulative disease indexb
No treatment	17	0.76 ± 0.18	1.24 ± 0.18	2.29 ± 0.27	16.65 ± 3.33
Acthar	16	1.09 ± 0.06	1.06 ± 0.06	*1.44 ± 0.22	*7.78 ± 2.10
Placebo gel	16	1.53 ± 0.22	1.69 ± 0.22	2.41 ± 0.30	16.72 ± 2.79

Mice were immunized with PLP_139-151 and treated every other day.

^aPeak clinical score = the peak score for each mouse for all mice within a group over the entire 2nd attack were averaged.

^bCumulative disease index = all of the scores for all of the mice within a group over the entire 2nd attack were averaged. Data represent the mean ± SEM.

^*p<0.05, t test.